The estimated Net Worth of Herm Rosenman is at least $19.7 Миллион dollars as of 16 February 2024. Mr. Rosenman owns over 93,901 units of Natera Inc stock worth over $19,266,214 and over the last 18 years he sold NTRA stock worth over $0. In addition, he makes $479,235 as Independent Director at Natera Inc.
Herman has made over 17 trades of the Natera Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 93,901 units of NTRA stock worth $249,777 on 16 February 2024.
The largest trade he's ever made was buying 100,000 units of Natera Inc stock on 21 May 2018 worth over $81,000. On average, Herman trades about 5,246 units every 34 days since 2006. As of 16 February 2024 he still owns at least 155,586 units of Natera Inc stock.
You can see the complete history of Mr. Rosenman stock trades at the bottom of the page.
Herman (Herm) Rosenman CPA serves as Independent Director of the Company. He served as Chief Financial Officer of Natera Inc. Mr. Herm Rosenman has served as our Chief Financial Officer since February 2014. Previously, he held the position of Senior Vice President—Finance and Chief Financial Officer at Gen-Probe Incorporated, a developer, manufacturer and marketer of nucleic acid probe-based products used for the clinical diagnosis of human diseases and for screening donated human blood, from June 2001 to April 2012, when Gen-Probe was acquired by Hologic, Inc., a developer, manufacturer and supplier of diagnostic products, medical imaging systems, and surgical products. From April 2012 to February 2014, Mr. Rosenman focused on his board memberships. Prior to joining Gen-Probe, he was President and Chief Executive Officer of Ultra Acquisition Corp., a retail chain and consumer products manufacturer, from 1997 to 2000. Mr. Rosenman has served on the board of directors of Oxford Immunotec Global PLC, a commercial-stage diagnostics company, since 2013. Mr. Rosenman served on the board of directors of Medistem, Inc., a stem cell therapy company, from 2013 to 2014. Medistem, Inc. was acquired by Intrexon Corporation, a synthetic biology company. Mr. Rosenman served on the board of directors of ARYx Therapeutics Inc., a private drug discovery and development company, from 2006 to 2009. Mr. Rosenman served on the board of directors of Infinity Pharmaceuticals, Inc., a drug discovery and development company, where he served as Chairman of the Audit Committee from 2003 to 2007. He has also served on the board of directors of a number of privately held companies. Mr. Rosenman holds a B.B.A. in accounting and finance from Pace University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania.
As the Independent Director of Natera Inc, the total compensation of Herman Rosenman at Natera Inc is $479,235. There are 15 executives at Natera Inc getting paid more, with Steven Chapman having the highest compensation of $6,200,910.
Herman Rosenman is 72, he's been the Independent Director of Natera Inc since 2020. There are no older and 17 younger executives at Natera Inc.
Herm's mailing address filed with the SEC is C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN, TX, 78753.
Over the last 14 years, insiders at Natera Inc have traded over $290,138,276 worth of Natera Inc stock and bought 2,046,493 units worth $38,018,986 . The most active insiders traders include Matthew Rabinowitz, James Healy и Roelof Botha. On average, Natera Inc executives and independent directors trade stock every 9 days with the average trade being worth of $3,415,231. The most recent stock trade was executed by Steven Leonard Chapman on 15 August 2024, trading 5,583 units of NTRA stock currently worth $663,875.
natera is a san carlos, ca-based company that is driven by a passion for elevating the science and utility of prenatal testing. the advent of the information age has created a paradigm shift in the fields of computing and informatics. surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing. until natera. from conception to delivery, natera is pioneering next-generation accuracy and reliability in preconception and prenatal genetic testing services, enabling couples to be informed about their pregnancy each step of the way. the company offers a wide range of tests from preimplantation genetic diagnosis (pgd) for ivf to breakthrough advances in the field of non-invasive prenatal testing (nipt). using advances from the human genome project and powered by sophisticated proprietary bioinformatic algorithms, natera’s comprehensive portfolio of tests, proven science, and experienced genetic counseling services deliver the most accurate results in the
Natera Inc executives and other stock owners filed with the SEC include: